Composite Aging Biomarker Panel
Evidence reviewed
Research-stage DNA methylation age and pace-of-aging measures with bounded utility claims.
Boundary: Does not establish diagnosis, clinical utility or a definitive biological-age reading.
LongevityNext discovery hub
Biomarkers
Research-stage measures, validation boundaries and claim-risk context.
Source-reviewed hub
10 source-reviewed records
Source-reviewed intelligence
Section intelligence
Directly related records lead this section.
Immune Age Signals
Evidence reviewed
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
Consumer Biomarker Claims Watch
Evidence reviewed
Regulatory claim-risk context for consumer biomarkers and direct-to-consumer tests.
Boundary: Not legal advice, biological evidence or a product-specific finding.
Source-reviewed intelligence
Related intelligence
Additional directly related records follow the section-specific lead set.
Chronic Inflammation in Aging: Evidence Map, Measures, and Intervention Limits
Evidence reviewed
Maps inflammaging definitions, human measures, outcome associations, mechanisms and intervention limits.
Boundary: Inflammatory markers and their reduction are not validated proof of slower aging or longevity benefit.
What DO-HEALTH Actually Tested: Omega-3, Biomarker Aging, and Endpoint Limits
Evidence reviewed
Separates DO-HEALTH's null primary clinical endpoint family from a later small post hoc DNA-methylation signal.
Boundary: Clock changes are not proof of slower clinical aging, healthspan or lifespan.
Aging Biomarkers Compared: What Each Measure Captures—and What It Cannot Prove
Evidence reviewed
Compares molecular, organ-level, functional and clinical aging measures by intended use, validation and limits.
Boundary: Age prediction, outcome association or intervention response does not establish a validated aging-rate or clinical surrogate.
Aging Trial Endpoints: A Role-Based Interpretation Framework Without False Equivalence
Evidence reviewed
A role-based framework for reading trial endpoints, estimands, multiplicity, clinical meaning and surrogate claims.
Boundary: Endpoint labels alone do not establish confirmatory force or clinical importance.
From Preclinical Promise to Human Evidence: How to Read a Longevity Translation Claim
Evidence reviewed
A claim-to-evidence framework separating exposure, target engagement, biomarker movement, safety and clinical benefit.
Boundary: Interpretive context does not establish that an intervention works.
From 9 to 12 Hallmarks: What the Aging Framework Explains—and What It Does Not
Evidence reviewed
The aging Hallmarks are an influential research framework, not a complete causal theory, treatment checklist or validated endpoint set.
Boundary: Framework context does not validate an intervention, biomarker or clinical endpoint.
BioAge Labs
Evidence reviewed
Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.
Boundary: Pipeline and source mapping, not clinical validation or investment analysis.
LN Pro preview